OncoMatch/Clinical Trials/NCT05950594

IVIM & OLINK in Sarcoma

Is NCT05950594 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for soft tissue sarcoma.

Phase 2RecruitingUniversity Health Network, TorontoNCT05950594Data as of May 2026

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify